Home・Aktien・Emergent BioSolutions Inc

Emergent BioSolutions Inc

Geschlossen

BrancheGesundheitswesen

5.89 -1.17

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.73

Max

Schlüsselkennzahlen
By Trading Economics
Einkommen	-187M -180M
Verkäufe	78M 234M
KGV Branchendurchschnitt	8.634 57.366
EPS	0.6
Gewinnspanne	-76.91
Angestellte	900
EBITDA	-205M -156M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+67.5% upside

Dividenden
By Acuity
Nächstes Ergebnis	28. Okt. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-112M 266M
Vorheriger Eröffnungskurs	7.06
Vorheriger Schlusskurs	5.89

Nachrichtenstimmung

By Acuity

20%

80%

46 / 340 Ranking in Healthcare

Emergent BioSolutions Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Emergent BioSolutions Inc Prognose

Kursziel

By TipRanks

67.5% Vorteil

12-Monats-Prognose

Durchschnitt 10 USD 67.5%

Hoch 10 USD

Tief 10 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Emergent BioSolutions Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Emergent BioSolutions Inc – Dist abgegeben haben.

Stimmung

By Acuity

46 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.